SVA (Sinovac Biotech) Interest Expense: $-10.5 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SVA Sinovac Biotech Ltd SVA
12 GF Score
Price $6.47
! 9 Warning Signs
View Full Analysis

What is Sinovac Biotech Interest Expense?

Sinovac Biotech SVA 12 Interest Expense is $-10.5 Mil as of Jun. 2026. GuruFocus rates SVA with a GF Score™ of 12/100. The stock has 9 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sinovac Biotech's interest expense for the six months ended in Jun. 2026 was $ -4.8 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was $-10.5 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sinovac Biotech's Operating Income for the six months ended in Jun. 2026 was $ -118.0 Mil. Sinovac Biotech's Interest Expense for the six months ended in Jun. 2026 was $ -4.8 Mil. Sinovac Biotech did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sinovac Biotech  (NAS:SVA) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sinovac Biotech's Interest Expense for the six months ended in Jun. 2026 was $-4.8 Mil. Its Operating Income for the six months ended in Jun. 2026 was $-118.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2026 was $240.8 Mil.

Sinovac Biotech's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Sinovac Biotech did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Sinovac Biotech Interest Expense Historical Data

* Premium members only.

The historical data trend for Sinovac Biotech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinovac Biotech Interest Expense Chart

Sinovac Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.84 -1.26 -4.94 -5.64 -9.82

Sinovac Biotech Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.18 -3.46 -4.10 -5.72 -4.77
SVA
12GF Score
Sinovac Biotech Ltd SVA
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinovac Biotech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-10.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-10.5 Mil mean?
Sinovac Biotech (SVA) has a Interest Expense of $-10.5 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sinovac Biotech and its competitors.
Is Sinovac Biotech's Interest Expense too high?
Sinovac Biotech's current Interest Expense is $-10.5 Mil. Overall, Sinovac Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sinovac Biotech's Interest Expense compare to INBX and HLVX?
Sinovac Biotech's Interest Expense of $-10.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sinovac Biotech and its competitors. Sinovac Biotech's current Interest Expense is $-10.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinovac Biotech stock overvalued right now?
Sinovac Biotech (SVA) has a current Interest Expense of $-10.5 Mil. The current Interest Expense is $-10.5 Mil. Sinovac Biotech's overall GF Score™ is 12/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Sinovac Biotech (SVA), the current Interest Expense is $-10.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sinovac Biotech Business Description

Address No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.
12GF Score

Get the complete analysis for SVA

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.47
Price